De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. Physical illness in patients with severe mental disorders I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52–77.
De Hert M, Cohen D, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndetei DM, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry. 2011;10(2):138–51.
National Health Service England. Improving physical healthcare for people living with severe mental illness (SMI) in primary care: Guidance for CCGs. 2018. https://www.england.nhs.uk/wp-content/uploads/2018/02/improving-physical-health-care-for-smi-in-primary-care.pdf Accessed 29th October 2020.
National Mental Health Commission. Equally Well Consensus Statement: Improving the physical health and wellbeing of people living with mental illness in Australia. 2016. https://www.equallywell.org.au/wp-content/uploads/2018/12/Equally-Well-National-Consensus-Booklet-47537.pdf Accessed 29th October 2020.
Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiat. 2015;72(4):334–41.
Reilly S, Olier I, Planner C, Doran T, Reeves D, Ashcroft DM, et al. Inequalities in physical comorbidity: a longitudinal comparative cohort study of people with severe mental illness in the UK. BMJ Open. 2015;5(12):e009010.
National Institute for Health and Care Excellence. Multimorbidity: Clinical Assessment and Management (NG 56). 2016. https://www.nice.org.uk/guidance/ng56/resources/multimorbidity-clinical-assessment-and-management-pdf-1837516654789 Accessed 29th October 2020.
Lawrence D, Hancock KJ, Kisely S. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ. 2013;346:f2539.
Naylor C, Das P, Ross S, Honeyman M, Thompson J, Gilburt H. The Kings Fund: Bringing Together Physical Health and Mental Health. 2016. https://www.kingsfund.org.uk/publications/physical-and-mental-health Accessed 29th October 2020.
Laursen TM, Munk-Olsen T, Agerbo E, Gasse C, Mortensen PB. Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry. 2009;66(7):713–20.
Lawrence D HC, Jablensky AV. . Preventable Physical Illness in People with Mental Illness. The University of Western Australia. 2001(Online).
Baxter AJ, Harris MG, Khatib Y, Brugha TS, Bien H, Bhui K. Reducing excess mortality due to chronic disease in people with severe mental illness: meta-review of health interventions. Br J Psychiatry. 2016;208(4):322–9.
Vermeulen J, van Rooijen G, Doedens P, Numminen E, van Tricht M, de Haan L. Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis. Psychol Med. 2017;47(13):2217–28.
Velligan DI, Sajatovic M, Hatch A, Kramata P, Docherty JP. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449–68.
Alshehri GH, Keers RN, Ashcroft DM. Frequency and Nature of Medication Errors and Adverse Drug Events in Mental Health Hospitals: a Systematic Review. Drug Saf. 2017;40(10):871–86.
Doherty AM, Gaughran F. The interface of physical and mental health. Soc Psychiatry Psychiatr Epidemiol. 2014;49(5):673–82.
Morgan VA, Waterreus A, Jablensky A, Mackinnon A, McGrath JJ, Carr V, et al. People living with psychotic illness in 2010: the second Australian national survey of psychosis. Aust N Z J Psychiatry. 2012;46(8):735–52.
Morant N, Azam K, Johnson S, Moncrieff J. The least worst option: user experiences of antipsychotic medication and lack of involvement in medication decisions in a UK community sample. J Ment Health. 2018;27(4):322–8.
Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull. 2013;39(2):295–305.
Keating D, McWilliams S, Schneider I, Hynes C, Cousins G, Strawbridge J, et al. Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. BMJ Open. 2017;7(1):e013881.
Hynes C, McWilliams S, Clarke M, Fitzgerald I, Feeney L, Taylor M, et al. Check the effects: systematic assessment of antipsychotic side-effects in an inpatient cohort. Therapeutic Advances in Psychopharmacology. 2020;10:2045125320957119.
Royal College of Psychiatrists. Report of the National Audit of Schizophrenia (NAS) 2012. 2012. https://www.rcpsych.ac.uk/docs/default-source/improving-care/ccqi/national-clinical-audits/ncap-library/national-audit-of-schizophrenia-document-library/nas-round-1-executive-summary.pdf?sfvrsn=670e8bee_4 Accessed 29th October 2020.
Gilbody S, Peckham E, Bailey D, Arundel C, Heron P, Crosland S, et al. Smoking cessation for people with severe mental illness (SCIMITAR+): a pragmatic randomised controlled trial. Lancet Psychiatry. 2019;6(5):379–90.
Royal College of Psychiatrists. Healthcare Quality Improvement Partnership. National Clinical Audit of Psychosis – National Report for the Core Audit 2018. https://www.rcpsych.ac.uk/docs/default-source/improving-care/ccqi/national-clinical-audits/ncap-library/ncap-exec-summary-report-core-audit-2018.pdf?sfvrsn=f4be1682_2 Accessed 29th October 2020.
Cooper SJ, Reynolds GP,With expert c-a, Barnes T, England E, Haddad PM, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016;30(8):717–48.
Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37–43.
Boyd CMFM. Future of Multimorbidity Research: How Should Understanding of Multimorbidity Inform Health System Design? Public Health Rev. 2010;32:451–74.
World Health Organization. Medication safety in high-risk situations. World Health Organization; 2019. https://apps.who.int/iris/handle/10665/325131 Acccessed 29th October 2020.
Lawrence D, Kisely S. Inequalities in healthcare provision for people with severe mental illness. J Psychopharmacol. 2010;24(4 Suppl):61–8.
Royal College of Psychiatrists. Whole person care: From rhetoric to reality. Achieving parity between mental and physical health. Occasional Paper 88. 2013. https://www.drugsandalcohol.ie/19579/1/RCP_Occasional_paper_88.pdf Accessed 29th October 2020.
Fond G, Salas S, Pauly V, Baumstarck K, Bernard C, Orleans V, et al. End-of-life care among patients with schizophrenia and cancer: a population-based cohort study from the French national hospital database. Lancet Public Health. 2019;4(11):e583–91.
Carolan A, Keating D, Strawbridge J, Ryan C. Optimising prescribing for patients with severe mental illness: the need for criteria. Evid Based Ment Health. 2019;22(4):139–41.
Phull J NV. The use of a Lester Tool-based physical health app in mental health inpatient settings. Mental Health Practice. 2019;7(22(2)).
Royal Pharmaceutical Society. Medicines Optimisation: Helping patients to make the most of medicines. Good practice guidance for healthcare professionals in England. 2013. https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/Policy/helping-patients-make-the-most-of-their-medicines.pdf Accessed 29th October 2020.
Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83.
American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015;63(11):2227–46.
Lavan AH, Gallagher P, Parsons C, O’Mahony D. STOPPFrail (Screening Tool of Older Persons Prescriptions in Frail adults with limited life expectancy): consensus validation. Age Ageing. 2017;46(4):600–7.
Barry E, O’Brien K, Moriarty F, Cooper J, Redmond P, Hughes CM, et al. PIPc study: development of indicators of potentially inappropriate prescribing in children (PIPc) in primary care using a modified Delphi technique. BMJ Open. 2016;6(9):e012079.
Cooper JA, Ryan C, Smith SM, Wallace E, Bennett K, Cahir C, et al. The development of the PROMPT (PRescribing Optimally in Middle-aged People’s Treatments) criteria. BMC Health Serv Res. 2014;14:484.
Ryan C, O’Mahony D, Kennedy J, Weedle P, Cottrell E, Heffernan M, et al. Potentially inappropriate prescribing in older residents in Irish nursing homes. Age Ageing. 2012;42(1):116–20.
O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–8.
Hill-Taylor B, Sketris I, Hayden J, Byrne S, O’Sullivan D, Christie R. Application of the STOPP/START criteria: a systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact. J Clin Pharm Ther. 2013;38(5):360–72.
Avery AJ, Rodgers S, Cantrill JA, Armstrong S, Cresswell K, Eden M, et al. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. Lancet. 2012;379(9823):1310–9.
Lavan AH, O’Mahony D, Gallagher P, Fordham R, Flanagan E, Dahly D, et al. The effect of SENATOR (Software ENgine for the Assessment and optimisation of drug and non-drug Therapy in Older peRsons) on incident adverse drug reactions (ADRs) in an older hospital cohort - Trial Protocol. BMC Geriatr. 2019;19(1):40.
PRIMIS. PINCER National Rollout Progress Report to NHS England and the AHSN Network2020. Available from: https://www.nottingham.ac.uk/primis/documents/pincer/pincer-progress-report-july-2020.pdf.
Peek N, Gude WT, Keers RN, Williams R, Kontopantelis E, Jeffries M, et al. Evaluation of a pharmacist-led actionable audit and feedback intervention for improving medication safety in UK primary care: An interrupted time series analysis. PLoS Med. 2020;17(10):e1003286.
Khawagi WY, Steinke DT, Nguyen J, Keers RN. Identifying potential prescribing safety indicators related to mental health disorders and medications: A systematic review. PLoS ONE. 2019;14(5):e0217406.
Keers RN, Williams SD, Vattakatuchery JJ, Brown P, Miller J, Prescott L, et al. Prevalence, nature and predictors of prescribing errors in mental health hospitals: a prospective multicentre study. BMJ Open. 2014;4(9):e006084.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. biometrics. 1977:159–74.
Ryan C, O’Mahony D, Byrne S. Application of STOPP and START criteria: interrater reliability among pharmacists. Ann Pharmacother. 2009;43(7):1239–44.
Gallagher P, Baeyens JP, Topinkova E, Madlova P, Cherubini A, Gasperini B, et al. Inter-rater reliability of STOPP (Screening Tool of Older Persons’ Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment) criteria amongst physicians in six European countries. Age Ageing. 2009;38(5):603–6.
Dalkey NC. Delphi. Rand Corp Santa Monica CA. 1967. https://apps.dtic.mil/sti/pdfs/AD0660554.pdf Accessed 29th October 2020.
Lavan AH, Gallagher P, O’Mahony D. Inter-rater reliability of STOPPFrail [Screening Tool of Older Persons Prescriptions in Frail adults with limited life expectancy] criteria amongst 12 physicians. Eur J Clin Pharmacol. 2018;74(3):331–8.
Khawagi WY, Steinke DT, Nguyen J, Pontefract S, Keers RN. Development of prescribing safety indicators related to mental health disorders and medications: Modified e-Delphi study. Br J Clin Pharmacol. 2020.
Royal College of Psychiatrists Working Group for Improving the Physical Health of People with SMI. Improving the physical health of adults with severe mental illness: essential actions (OP100). Royal College of Psychiatrists. 2016. https://www.aomrc.org.uk/wp-content/uploads/2016/10/Improving_-physical_health_adults_with_SMI_essential_actions_251016-2.pdf Accessed 29th October 2020.
Burns A, Lucey JV, Strawbridge J, Clancy L, Doyle F. Prospective study of provided smoking cessation care in an inpatient psychiatric setting. J Psychosom Res. 2018;115:24–31.
Lawrence W, Black C, Tinati T, Cradock S, Begum R, Jarman M, et al. ‘Making every contact count’: evaluation of the impact of an intervention to train health and social care practitioners in skills to support health behaviour change. J Health Psychol. 2016;21(2):138–51.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140–205.
Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. bmj. 2017;357:j2099.
Cunningham R, Poppe K, Peterson D, Every-Palmer S, Soosay I, Jackson R. Prediction of cardiovascular disease risk among people with severe mental illness: A cohort study. PLoS ONE. 2019;14(9): e0221521.
Barbui C, Conti V, Cipriani A. Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studies. Drug Saf. 2014;37(2):79–90.
Zhang R, Dong L, Shao F, Tan X, Ying K. Antipsychotics and venous thromboembolism risk: a meta-analysis. Pharmacopsychiatry. 2011;44(05):183–8.
Purcell A, Clarke M, Maidment I. Venous thromboembolism prophylaxis in mental health in-patient services: a qualitative study. Int J Clin Pharm. 2018;40(3):543–9.
Health Service Executive. VTE Prophylaxis Protocol for In-Patients aged 16 or Over with COVID-19 or Medical Conditions. 2020. https://hse.drsteevenslibrary.ie/c.php?g=679077&p=4866382#VTE%20Prophylaxis%20Protocol%20for%20In-Patients%20aged%2016%20or%20Over%20with%20COVID-19%20or%20Medical%20Conditions120 Accessed 29th October 2020.
O’Mahony D. STOPP/START criteria for potentially inappropriate medications/potential prescribing omissions in older people: origin and progress. Expert Rev Clin Pharmacol. 2020;13(1):15–22.
Adam L, Moutzouri E, Baumgartner C, Loewe AL, Feller M, M’Rabet-Bensalah K, et al. Rationale and design of OPtimising thERapy to prevent Avoidable hospital admissions in Multimorbid older people (OPERAM): a cluster randomised controlled trial. BMJ Open. 2019;9(6):e026769.
De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26(3):144–58.
Hernandez B, Reilly RB, Kenny RA. Investigation of multimorbidity and prevalent disease combinations in older Irish adults using network analysis and association rules. Sci Rep. 2019;9(1):14567.
Morgan SG, Weymann D, Pratt B, Smolina K, Gladstone EJ, Raymond C, et al. Sex differences in the risk of receiving potentially inappropriate prescriptions among older adults. Age Ageing. 2016;45(4):535–42.